Real-world safety profile of elexacaftor/tezacaftor/ivacaftor: a disproportionality analysis using the U.S. FDA adverse event reporting system
BackgroundElexacaftor/Tezacaftor/Ivacaftor (ETI) has demonstrated significant efficacy in enhancing clinical outcomes for patients with cystic fibrosis (CF). Despite this, comprehensive post-marketing assessments of its adverse drug events (ADEs) remain insufficient. This study aims to analyze the A...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-03-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2025.1531514/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850069177742655488 |
|---|---|
| author | Chengyu Zhu Zhiwei Cui Tingting Liu Siyu Lou Linmei Zhou Junyou Chen Ruizhen Zhao Li Wang Yingyong Ou Fan Zou |
| author_facet | Chengyu Zhu Zhiwei Cui Tingting Liu Siyu Lou Linmei Zhou Junyou Chen Ruizhen Zhao Li Wang Yingyong Ou Fan Zou |
| author_sort | Chengyu Zhu |
| collection | DOAJ |
| description | BackgroundElexacaftor/Tezacaftor/Ivacaftor (ETI) has demonstrated significant efficacy in enhancing clinical outcomes for patients with cystic fibrosis (CF). Despite this, comprehensive post-marketing assessments of its adverse drug events (ADEs) remain insufficient. This study aims to analyze the ADEs associated with ETI using the U.S. FDA Adverse Event Reporting System (FAERS).MethodsWe conducted a pharmacovigilance analysis utilizing FAERS data from Q4 2019 to Q3 2024. Reports of ADEs related to ETI were extracted, and disproportionality analyses—including Reporting Odds Ratio (ROR), Proportional Reporting Ratio (PRR), Bayesian Confidence Propagation Neural Network (BCPNN), and Multi-item Gamma Poisson Shrinker (MGPS)—were employed to evaluate signal strength. Additionally, a time-to-onset (TTO) analysis was performed.ResultsA total of 28,366 ETI-related ADEs were identified, spanning 27 organ systems. We identified 322 positive signals, with signals consistent with the drug label including headache (702 cases, ROR 2.75), infective pulmonary exacerbation of CF (691 cases, ROR 384.24), rash (538 cases, ROR 2.72), and cough (507 cases, ROR 3.79). Unexpected signals were also noted, such as anxiety (494 cases, ROR 4.16), depression (364 cases, ROR 4.59), insomnia (281 cases ROR 2.83), nephrolithiasis (79 cases, ROR 3.63) and perinatal depression (4 cases, ROR 13.59). The TTO analysis indicated that the median onset of ADEs was 70 days, with 37.08% occurring within the first month. Subgroup analyses revealed that females exhibited a higher reporting rank for mental disorder and constipation, whereas in males, they were insomnia, abdominal pain, and nasopharyngitis.ConclusionThis study highlights both recognized and unexpected ADEs associated with ETI, underscoring the necessity for ongoing monitoring, particularly concerning psychiatric conditions. The subgroup analysis suggests a need for personalized treatment strategies to optimize patient care. |
| format | Article |
| id | doaj-art-daf3994210724bcd9df3dda143e6f79f |
| institution | DOAJ |
| issn | 1663-9812 |
| language | English |
| publishDate | 2025-03-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pharmacology |
| spelling | doaj-art-daf3994210724bcd9df3dda143e6f79f2025-08-20T02:47:50ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122025-03-011610.3389/fphar.2025.15315141531514Real-world safety profile of elexacaftor/tezacaftor/ivacaftor: a disproportionality analysis using the U.S. FDA adverse event reporting systemChengyu Zhu0Zhiwei Cui1Tingting Liu2Siyu Lou3Linmei Zhou4Junyou Chen5Ruizhen Zhao6Li Wang7Yingyong Ou8Fan Zou9Department of Respiratory and Critical Care Medicine, Affiliated Hospital of Zunyi Medical University, Zunyi, ChinaDepartment of Obstetrics and Gynecology, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, ChinaDepartment of Respiratory and Critical Care Medicine, Affiliated Hospital of Zunyi Medical University, Zunyi, ChinaDepartment of Respiratory and Critical Care Medicine, Affiliated Hospital of Zunyi Medical University, Zunyi, ChinaDepartment of Respiratory and Critical Care Medicine, Affiliated Hospital of Zunyi Medical University, Zunyi, ChinaDepartment of Respiratory and Critical Care Medicine, Affiliated Hospital of Zunyi Medical University, Zunyi, ChinaDepartment of Respiratory and Critical Care Medicine, Affiliated Hospital of Zunyi Medical University, Zunyi, ChinaDepartment of Respiratory and Critical Care Medicine, Affiliated Hospital of Zunyi Medical University, Zunyi, ChinaDepartment of Respiratory and Critical Care Medicine, Affiliated Hospital of Zunyi Medical University, Zunyi, ChinaDepartment of Respiratory and Critical Care Medicine, Affiliated Hospital of Zunyi Medical University, Zunyi, ChinaBackgroundElexacaftor/Tezacaftor/Ivacaftor (ETI) has demonstrated significant efficacy in enhancing clinical outcomes for patients with cystic fibrosis (CF). Despite this, comprehensive post-marketing assessments of its adverse drug events (ADEs) remain insufficient. This study aims to analyze the ADEs associated with ETI using the U.S. FDA Adverse Event Reporting System (FAERS).MethodsWe conducted a pharmacovigilance analysis utilizing FAERS data from Q4 2019 to Q3 2024. Reports of ADEs related to ETI were extracted, and disproportionality analyses—including Reporting Odds Ratio (ROR), Proportional Reporting Ratio (PRR), Bayesian Confidence Propagation Neural Network (BCPNN), and Multi-item Gamma Poisson Shrinker (MGPS)—were employed to evaluate signal strength. Additionally, a time-to-onset (TTO) analysis was performed.ResultsA total of 28,366 ETI-related ADEs were identified, spanning 27 organ systems. We identified 322 positive signals, with signals consistent with the drug label including headache (702 cases, ROR 2.75), infective pulmonary exacerbation of CF (691 cases, ROR 384.24), rash (538 cases, ROR 2.72), and cough (507 cases, ROR 3.79). Unexpected signals were also noted, such as anxiety (494 cases, ROR 4.16), depression (364 cases, ROR 4.59), insomnia (281 cases ROR 2.83), nephrolithiasis (79 cases, ROR 3.63) and perinatal depression (4 cases, ROR 13.59). The TTO analysis indicated that the median onset of ADEs was 70 days, with 37.08% occurring within the first month. Subgroup analyses revealed that females exhibited a higher reporting rank for mental disorder and constipation, whereas in males, they were insomnia, abdominal pain, and nasopharyngitis.ConclusionThis study highlights both recognized and unexpected ADEs associated with ETI, underscoring the necessity for ongoing monitoring, particularly concerning psychiatric conditions. The subgroup analysis suggests a need for personalized treatment strategies to optimize patient care.https://www.frontiersin.org/articles/10.3389/fphar.2025.1531514/fullCFTR modulatorpharmacovigilanceFAERSreal world analysisadverse drug events |
| spellingShingle | Chengyu Zhu Zhiwei Cui Tingting Liu Siyu Lou Linmei Zhou Junyou Chen Ruizhen Zhao Li Wang Yingyong Ou Fan Zou Real-world safety profile of elexacaftor/tezacaftor/ivacaftor: a disproportionality analysis using the U.S. FDA adverse event reporting system Frontiers in Pharmacology CFTR modulator pharmacovigilance FAERS real world analysis adverse drug events |
| title | Real-world safety profile of elexacaftor/tezacaftor/ivacaftor: a disproportionality analysis using the U.S. FDA adverse event reporting system |
| title_full | Real-world safety profile of elexacaftor/tezacaftor/ivacaftor: a disproportionality analysis using the U.S. FDA adverse event reporting system |
| title_fullStr | Real-world safety profile of elexacaftor/tezacaftor/ivacaftor: a disproportionality analysis using the U.S. FDA adverse event reporting system |
| title_full_unstemmed | Real-world safety profile of elexacaftor/tezacaftor/ivacaftor: a disproportionality analysis using the U.S. FDA adverse event reporting system |
| title_short | Real-world safety profile of elexacaftor/tezacaftor/ivacaftor: a disproportionality analysis using the U.S. FDA adverse event reporting system |
| title_sort | real world safety profile of elexacaftor tezacaftor ivacaftor a disproportionality analysis using the u s fda adverse event reporting system |
| topic | CFTR modulator pharmacovigilance FAERS real world analysis adverse drug events |
| url | https://www.frontiersin.org/articles/10.3389/fphar.2025.1531514/full |
| work_keys_str_mv | AT chengyuzhu realworldsafetyprofileofelexacaftortezacaftorivacaftoradisproportionalityanalysisusingtheusfdaadverseeventreportingsystem AT zhiweicui realworldsafetyprofileofelexacaftortezacaftorivacaftoradisproportionalityanalysisusingtheusfdaadverseeventreportingsystem AT tingtingliu realworldsafetyprofileofelexacaftortezacaftorivacaftoradisproportionalityanalysisusingtheusfdaadverseeventreportingsystem AT siyulou realworldsafetyprofileofelexacaftortezacaftorivacaftoradisproportionalityanalysisusingtheusfdaadverseeventreportingsystem AT linmeizhou realworldsafetyprofileofelexacaftortezacaftorivacaftoradisproportionalityanalysisusingtheusfdaadverseeventreportingsystem AT junyouchen realworldsafetyprofileofelexacaftortezacaftorivacaftoradisproportionalityanalysisusingtheusfdaadverseeventreportingsystem AT ruizhenzhao realworldsafetyprofileofelexacaftortezacaftorivacaftoradisproportionalityanalysisusingtheusfdaadverseeventreportingsystem AT liwang realworldsafetyprofileofelexacaftortezacaftorivacaftoradisproportionalityanalysisusingtheusfdaadverseeventreportingsystem AT yingyongou realworldsafetyprofileofelexacaftortezacaftorivacaftoradisproportionalityanalysisusingtheusfdaadverseeventreportingsystem AT fanzou realworldsafetyprofileofelexacaftortezacaftorivacaftoradisproportionalityanalysisusingtheusfdaadverseeventreportingsystem |